🇺🇸 FDA
Patent

US 12247037

1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders

granted A61PA61P25/18A61P25/22

Quick answer

US patent 12247037 (1-(2,6-diazaspiro[3.3]heptan-6-yl)-5,6-dihydro-4h-benzo[f][1,2,4]triazolo[4,3-A][1,4]diazepine derivatives and related compounds as vasopressin antagonists for the treatment of neuro-psychological disorders) held by Neumora Therapeutics, Inc. expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Neumora Therapeutics, Inc.
Grant date
Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
29
CPC classes
A61P, A61P25/18, A61P25/22, A61P25/24